Table 1.
Analyte concentration, pg/ml | ||||
---|---|---|---|---|
|
||||
RA synovial fibroblasts |
RA skin fibroblasts |
|||
Unstimulated | Galectin 3–stimulated | Unstimulated | Galectin 3–stimulated | |
bFGF | <10 | <10 | <10 | <10 |
G-CSF | – | – | – | – |
VEGF | 10.1–50 | 50.1–100 | – | <10 |
IFNγ | – | – | – | – |
IFNα | – | – | – | – |
IL-1β | <10 | <10 | <10 | <10 |
CCL4 | <10 | 10.1–50 | <10 | <10 |
CXCL1 | <10 | 10.1–50 | – | <10 |
CXCL9 | 10.1–50 | 10.1–50 | 10.1–50 | 10.1–50 |
CXCL10 | – | <10 | – | – |
MMP-9 | <10 | <10 | <10 | <10 |
MMP-13 | – | – | – | – |
Supernatants from rheumatoid arthritis (RA) synovial fibroblasts were cultured in medium alone (unstimulated) or with 10 μg/ml of galectin 3, and were assayed by multiplex enzyme-linked immunosorbent assay (ELISA) for cytokines and chemokines, and by ELISA for IL-6 (lower detection limit 15 pg/ml). Duplicate wells for each sample were analyzed. Values are those obtained after background levels were subtracted. bFGF = basic fibroblast growth factor; G-CSF = granulocyte colony-stimulating factor; – = undetectable or <1 pg/ml; VEGF = vascular endothelial growth factor; IFNγ = interferon-γ; MMP-9 = matrix metalloproteinase 9.